For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according to a new study from The University of Texas MD Anderson Cancer Center.
The research, published in JAMA Oncology, reported an overall survival (OS) of 26.5 months. In contrast, the historical OS rate with standard...
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down...
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center...
Joint Statement from Dr. Joseph M. Herman, Clinical Research Director, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, and Dr. Markus Büchler, Chairman, Department of Surgery, University of Heidelberg
On Saturday, July 8, Dr. Joseph M. Herman of The University of Texas MD Anderson Cancer Center and Dr. Markus W Büchler of University of Heidelberg met with the medical team at the No. 1 Hospital...
The University of Texas MD Anderson Cancer Center today announced a new leadership structure designed to enhance teamwork and collaborative...
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard...
Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick, Ph.D....
The University of Texas MD Anderson Cancer Center plans its 19th annual Making Cancer History® seminar in Aspen, free and open to the public...
The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new...
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic...